Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
82 hedge funds and large institutions have $82.4M invested in Avadel Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 15 closing their positions.
19% more call options, than puts
Call options by funds: $2.87M | Put options by funds: $2.41M
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
1% more funds holding
Funds holding: 81 → 82 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.59% less ownership
Funds ownership: 60.74% → 57.15% (-3.6%)
67% less capital invested
Capital invested by funds: $252M → $82.4M (-$170M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GJL
Gendell Jeffrey L
|
+$5.84M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$3.24M |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$2.64M |
| 4 |
Two Sigma Investments
New York
|
+$1.92M |
| 5 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$11.4M |
| 2 |
Janus Henderson Group
London,
|
-$9.63M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$6.5M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.96M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$2.18M |
AVDL Hedge Fund Activity: Q2 2022 in Review
82 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2022, worth a combined $82.4M — down 67% from $252M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AVDL positions and 15 closed out — a net gain of 1 holder — while 23 added to existing stakes and 20 trimmed.
The largest buyer was Gendell Jeffrey L, adding an estimated $5.84M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $11.4M sold.
- 82 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2022, up from 81 in Q1 2022.
- Funds reported $82.4M of Avadel Pharmaceuticals stock for Q2 2022, down 67% quarter-over-quarter.
- 16 funds opened new Avadel Pharmaceuticals positions in Q2 2022 and 15 closed out, a net change of +1 holder.
- The largest Avadel Pharmaceuticals buyer in Q2 2022 was Gendell Jeffrey L, an estimated $5.84M added.
- The largest Avadel Pharmaceuticals seller in Q2 2022 was Avoro Capital Advisors, an estimated $11.4M sold.
Based on aggregated 13F filings for Q2 2022.